EpiPen’s 400 percent price hike tells us a lot about what’s wrong with American health care
▻http://www.vox.com/2016/8/23/12608316/epipen-price-mylan
We are the only developed nation that lets drugmakers set their own prices, maximizing profits the same way sellers of chairs, mugs, shoes, or any other manufactured goods would.
Sans voix...
▻http://thehill.com/policy/healthcare/293633-mylan-to-offer-cheaper-version-of-epipen-after-outcry
The company said the generic version, which will be identical to the branded product, will cost $300 for a pack of two, less than half of the current cost.
USA Today Helps Mylan Sell an Extortionate Price for EpiPen
▻http://fair.org/home/usa-today-helps-mylan-sell-an-extortionate-price-for-epipen
And if you go back to 2007, when Mylan acquired the rights to the EpiPen brand, the list price then for two devices was $94. That’s $109 in 2016 dollars—so, on that basis, Mylan’s generic EpiPen is actually a 175 percent price hike.
You don’t need time travel to make the generic EpiPen a bad deal, though; you just need to travel across the border into Canada, where a single pen retails for about $120 in Canadian money, which is about $92 in US currency. In France, where the device is made by a company Mylan recently bought, a twin-pack sells for about $85—or 28 percent of Mylan’s new “discount” price.
Raising prices exorbitantly so that you can present a slightly less extortionate price as a “sale” is a time-honored marketing tradition. USA Today is under no obligation to feature the scam in a headline, however.
Drugs and Privilege: Big Business, Congress and the EpiPen
▻http://www.truth-out.org/news/item/37456-drugs-and-privilege-big-business-congress-and-the-epipen
Like so many businesses eager to purchase politicians all their own, Mylan has made significant cash contributions to both sides of the aisle. Emmarie Huetteman at The New York Times reports, “Mylan’s political action committee has given at least $71,000 to congressional candidates from both parties this election cycle, according to the Center for Responsive Politics, with about 72 percent of those contributions going to Republicans.”
Opération #astroturf par Epipen
EpiPen Maker Lobbies to Shift High Costs to Others
▻http://www.nytimes.com/2016/09/16/business/epipen-maker-mylan-preventative-drug-campaign.html
An examination of the campaign by The New York Times, including a review of documents and interviews with more than a dozen people, shows that Mylan is well aware of that benefit and, in fact, has been helping orchestrate and pay for the effort.
Les «représentants» vont probablement s’empresser de servir le citoyen...